Estimations des analystes de Wall Street pour Plus Therapeutics, Inc. (PSTV): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 3 |
| Conserver | 1 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 4 |
| Note moyenne (1-5) | 0.75 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-08-13 | $-0.88 | ||
| 2026-05-15 | $-1.05 | $-0.95 | -10.5% |
| 2026-03-12 | $-0.83 | $-0.80 | -4.2% |
| 2025-10-30 | $-1.00 | $-0.50 | -100.0% |
| 2025-08-14 | $-0.25 | $-2.25 | +88.9% |
| 2025-05-30 | $-14.00 | $-4.25 | -229.4% |
| 2025-03-27 | $-16.75 | $-12.42 | -34.9% |
| 2024-11-14 | $-11.50 | $-11.50 | +0.0% |
Ratios de valorisation
| Prix / Valeur comptable | 4.80 |
| EV / EBITDA | -1.74 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $11.4M | $6.4M | $3.0M | $7.0M | $303000 | 0 | $224000 | $4.9M | $5.8M | $5.2M |
| Coût des Ventes | $2.7M | $1.3M | $1.1M | 0 | $2.7M | $66000 | $712000 | $9.7M | $852000 | $445000 |
| Marge Brute | $8.7M | $5.1M | $1.8M | $7.0M | -$2.4M | -$66000 | -$488000 | -$4.8M | $5.0M | $4.8M |
| R&D | $16.2M | $13.4M | $5.5M | $5.4M | $3.5M | $5.3M | $9.7M | $9.7M | $10.6M | $8.4M |
| Frais Généraux | $12.2M | $11.2M | $6.2M | $5.3M | $6.4M | $6.9M | $9.5M | $8.5M | $9.9M | $12.1M |
| Charges Opérationnelles | $28.4M | $25.8M | $10.8M | $10.7M | $7.2M | $12.4M | $19.2M | $8.5M | $19.7M | $20.1M |
| Résultat Opérationnel | -$19.7M | -$20.7M | -$8.8M | -$3.7M | -$9.6M | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M |
| EBITDA | -$18.3M | -$18.5M | -$6.6M | -$532000 | -$8.4M | -$12.0M | -$18.9M | -$12.3M | -$8.4M | -$18.3M |
| Charges d'Intérêt | $2.6M | $2.0M | $1.9M | $1.9M | $1.1M | $932000 | $711000 | $395000 | $3.7M | $3.6M |
| Résultat Avant Impôts | -$22.0M | -$22.7M | -$8.9M | -$3.3M | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| Impôts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Net | -$22.0M | -$22.7M | -$12.6M | -$10.9M | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
| BPA | $-240000000.00 | $-131345500.00 | $-32617500.00 | $-3101250.00 | $-697500.00 | $-444500.00 | $-288750.00 | $-106000.00 | $-48.75 | $-7.19 |
| BPA Dilué | $-240000000.00 | $-131345500.00 | $-32617500.00 | $-3452500.00 | $-697500.00 | $-444500.00 | $-288750.00 | $-106000.00 | $-58.50 | $-7.19 |
| Actions en Circulation (Diluées) | $692 | $17 | $0 | $4 | $12 | $32 | $70 | $126 | $308030 | $3.1M |
Prix
| Prix | $3.87 |
| Capitalisation | $9M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ADTX · BXRXQ · EDSA · MTVA · PHIO · RKTO
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de PSTV: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions